Showing 321-330 of 3239 results for "".
- Study: Oral Minoxidil Not Superior to Topical Minoxidilhttps://practicaldermatology.com/news/non-oral-and-topical-minoxidil/2467152/Daily oral minoxidil, 5 mg was not superior to topical minoxidil, 5%, in a population of male patients with alopecia according to a new study in JAMA Dermatology. "There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment," the autho
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://practicaldermatology.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit
- Survey Reveals Variation in Hyaluronidase Use in Aesthetic Practicehttps://practicaldermatology.com/news/survey-reveals-variation-hyaluronidase-use-aesthetic-practice/2466937/New research suggests a need for guidelines around the storage and dosing for hyaluronidase (HYAL) when using hyaluronic acid (HA) fillers. "Hyaluronic acids continue to be the fillers of choice worldwide and their popularity is growing," the authors wrote in Aesthetic Surgery Journa
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areatahttps://practicaldermatology.com/news/equillium-announces-positive-topline-data-phase-2-study-eq101-alopecia-areata/2466936/Equillium announced positive topline data from its phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA). The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101, as well as
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- Trifarotene Plus Skincare Effective Treatment for Acne-Induced Hyperpigmentationhttps://practicaldermatology.com/news/trifarotene-plus-skincare-effective-treatment-acne-induced-hyperpigmentation/2462920/Trifarotene combined with a skincare regimen was effective for the treatment of acne-induced hyperpigmentation (AIH) accompanying acne vulgaris (AV), according to results from a recent phase IV double-blind study. Researc
- Oral and Topical Minoxidil for Male Androgenetic Alopecia Show Similar Efficacy: Analysishttps://practicaldermatology.com/news/oral-and-topical-minoxidil-male-androgenetic-alopecia-similar-efficacy-analysis/2462791/Low-dose oral minoxidil (5 mg once daily) was found to have similar effectiveness to topical minoxidil (5% twice per day) for the treatment of male androgenetic alopecia (AGA). The authors conducted the double-blind, placebo-controlled randomized clinical trial in Brazil aiming to evalua
- Palm Phytonutrients To Be Displayed at Expohttps://practicaldermatology.com/news/palm-phytonutrients-be-displayed-expo/2462663/As the cosmeceutical market continues to expand, so does consumer interest in learning more about the key active ingredients in cosmeceutical products and how they work, according to a press release from palm phytonutrient manufacturer PhytoGaia. PhytoGaia, a manufacturer of palm phytonut